Abstract
Currently, coronavirus disease 2019 (COVID-19) has spread worldwide and continues to rise. There remains a significant unmet need for patients with hematological malignancies requiring specialized procedures and treatments, like cellular therapy to treat or cure their disease. For instance, chimeric antigen receptor T (CAR-T) cell therapy is approved for relapsed/refractory (after two or more lines of therapy) diffuse large B cell lymphoma and B cell acute lymphoblastic leukemia that is refractory or in the second relapse in patients younger than 25 years of age. Similarly, hematopoietic stem cell transplantation (HSCT) can be a lifesaving procedure for many patients, such as those with acute myeloid leukemia with high-risk cytogenetics. Unfortunately, the COVID-19 pandemic has thrust upon the hematologists and transplant specialists’ unique challenges with the implementation and management of cellular therapy. One of the significant concerns regarding this immunocompromised patient population is the significant risk of acquiring SARS-CoV-2 infection due to its highly contagious nature. Experts have recommended that if medically indicated, especially in high-risk disease (where chemotherapy is unlikely to work), these lifesaving procedures should not be delayed even during the COVID-19 pandemic. However, proceeding with CAR-T cell therapy and HSCT during the pandemic is a considerable task and requires dedication from the transplant team and buy-in from the patients and their family or support system. Open conversations should be held with the patients about the risks involved in undergoing cellular therapies during current times and the associated future uncertainties.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Ahmad A, Uddin S, Steinhoff M (2020) CAR-T cell therapies: an overview of clinical studies supporting their approved use against acute lymphoblastic leukemia and large B-cell lymphomas. Int J Mol Sci 21(11). https://doi.org/10.3390/ijms21113906
Al-Shamsi HO, Alhazzani W, Alhuraiji A, Coomes EA, Chemaly RF, Almuhanna M, Wolff RA, Ibrahim NK, Chua MLK, Hotte SJ, Meyers BM, Elfiki T, Curigliano G, Eng C, Grothey A, Xie C (2020) A practical approach to the management of cancer patients during the novel coronavirus disease 2019 (COVID-19) pandemic: an International Collaborative Group. Oncologist 25(6):e936–e945. https://doi.org/10.1634/theoncologist.2020-0213
Antonenas V, Garvin F, Webb M, Sartor M, Bradstock KF, Gottlieb D (2006) Fresh PBSC harvests, but not BM, show temperature-related loss of CD34 viability during storage and transport. Cytotherapy 8(2):158–165. https://doi.org/10.1080/14653240600620994
Ardura M, Hartley D, Dandoy C, Lehmann L, Jaglowski S, Auletta JJ (2020) Addressing the impact of the coronavirus disease 2019 (COVID-19) pandemic on hematopoietic cell transplantation: learning networks as a means for sharing best practices. Biol Blood Marrow Transplant 26(7):e147–e160. https://doi.org/10.1016/j.bbmt.2020.04.018
Bachanova V, Bishop MR, Dahi P, Dholaria B, Grupp SA, Hayes-Lattin B, Janakiram M, Maziarz RT, McGuirk JP, Nastoupil LJ, Oluwole OO, Perales MA, Porter DL, Riedell PA (2020) Chimeric antigen receptor T cell therapy during the COVID-19 pandemic. Biol Blood Marrow Transplant 26(7):1239–1246. https://doi.org/10.1016/j.bbmt.2020.04.008
Block KI (2020) Integrative cancer therapies: learning from COVID-19. Integr Cancer Ther 19:1534735420932652. https://doi.org/10.1177/1534735420932652
Boyiadzis MM, Dhodapkar MV, Brentjens RJ, Kochenderfer JN, Neelapu SS, Maus MV, Porter DL, Maloney DG, Grupp SA, Mackall CL, June CH, Bishop MR (2018) Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. J Immunother Cancer 6(1):137. https://doi.org/10.1186/s40425-018-0460-5
Broxmeyer HE, Parker GC (2020) Impact of COVID-19 and future emerging viruses on hematopoietic cell transplantation and other cellular therapies. Stem Cells Dev 29(10):625–626. https://doi.org/10.1089/scd.2020.0064
Brudno JN, Kochenderfer JN (2019) Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev 34:45–55. https://doi.org/10.1016/j.blre.2018.11.002
Dave H, Jerkins L, Hanley PJ, Bollard CM, Jacobsohn D (2019) Driving the CAR to the bone marrow transplant program. Curr Hematol Malig Rep 14(6):561–569. https://doi.org/10.1007/s11899-019-00544-6
Dholaria B, Savani BN (2020) How do we plan hematopoietic cell transplant and cellular therapy with the looming COVID-19 threat? Br J Haematol 189(2):239–240. https://doi.org/10.1111/bjh.16597
D’Souza A, Lee S, Zhu X, Pasquini M (2017) Current use and trends in hematopoietic cell transplantation in the United States. Biol Blood Marrow Transplant 23(9):1417–1421. https://doi.org/10.1016/j.bbmt.2017.05.035
Duncan MD, Wilkes DS (2005) Transplant-related immunosuppression: a review of immunosuppression and pulmonary infections. Proc Am Thorac Soc 2(5):449–455. https://doi.org/10.1513/pats.200507-073JS
Eapen M, Zhang MJ, Tang XY, Lee SJ, Fei MW, Wang HL, Hebert KM, Arora M, Chhabra S, Devine SM, Hamadani M, D’Souza A, Pasquini MC, Phelan R, Rizzo JD, Saber W, Shaw BE, Weisdorf DJ, Horowitz MM (2020) Hematopoietic cell transplantation with cryopreserved grafts for severe aplastic anemia. Biol Blood Marrow Transplant 26(7):e161–e166. https://doi.org/10.1016/j.bbmt.2020.04.027
Fournier D, Lewin A, Simard C, Trépanier P, Néron S, Ballerini L, Codinach M, Elmoazzen H, Halpenny M, Kogler G, Liedtke S, Louis I, Molluna CA, Pineault N, Prasath A, Querol S, Saccardi R, Sutherland DR, Thérien C, Urbani S (2020) Multi-laboratory assay for harmonization of enumeration of viable CD34+ and CD45+ cells in frozen cord blood units. Cytotherapy 22(1):44–51. https://doi.org/10.1016/j.jcyt.2019.10.009
Gardner RA, Ceppi F, Rivers J, Annesley C, Summers C, Taraseviciute A, Gust J, Leger KJ, Tarlock K, Cooper TM, Finney OC, Brakke H, Li DH, Park JR, Jensen MC (2019) Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy. Blood 134(24):2149–2158. https://doi.org/10.1182/blood.2019001463
Gehrie E, Tormey CA, Sanford KW (2020) Transfusion service response to the COVID-19 pandemic. Am J Clin Pathol. https://doi.org/10.1093/ajcp/aqaa111
Gibbs L, Minnelli N, Larrivee J, Sahu KK, Siddiqui AD (2020) Oncology dietitians sound alarm in key nutrition needs of cancer patients during COVID-19 pandemic. JCO Oncol Pract 2020:Op2000349. https://doi.org/10.1200/op.20.00349
Guttridge MG, Sidders C, Booth-Davey E, Pamphilon D, Watt SM (2006) Factors affecting volume reduction and red blood cell depletion of bone marrow on the COBE spectra cell separator before haematopoietic stem cell transplantation. Bone Marrow Transplant 38(3):175–181. https://doi.org/10.1038/sj.bmt.1705420
Hamadani M, Zhang MJ, Tang XY, Fei M, Brunstein C, Chhabra S, D’Souza A, Milano F, Phelan R, Saber W, Shaw BE, Weisdorf D, Devine SM, Horowitz MM (2020) Graft cryopreservation does not impact overall survival after allogeneic hematopoietic cell transplantation using post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant 26(7):1312–1317. https://doi.org/10.1016/j.bbmt.2020.04.001
Hassoun A, Thottacherry ED, Muklewicz J, Aziz QU, Edwards J (2020) Utilizing tocilizumab for the treatment of cytokine release syndrome in COVID-19. J Clin Virol 128:104443. https://doi.org/10.1016/j.jcv.2020.104443
Heeger PS, Dinavahi R (2012) Transplant immunology for non-immunologist. Mt Sinai J Med 79(3):376–387. https://doi.org/10.1002/msj.21314
Hunter BD, Rogalski M, Jacobson CA (2019) Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products. Expert Opin Biol Ther 19(11):1157–1164. https://doi.org/10.1080/14712598.2019.1644316
Jindal V, Sahu KK, Gaikazian S, Siddiqui AD, Jaiyesimi I (2020) Cancer treatment during COVID-19 pandemic. Med Oncol 37(7):58. https://doi.org/10.1007/s12032-020-01382-w
Kao GS, Kim HT, Daley H, Ritz J, Burger SR, Kelley L, Vierra-Green C, Flesch S, Spellman S, Miller J, Confer D (2011) Validation of short-term handling and storage conditions for marrow and peripheral blood stem cell products. Transfusion 51(1):137–147. https://doi.org/10.1111/j.1537-2995.2010.02758.x
Lal A, Mishra AK, Sahu KK (2020) CT chest findings in coronavirus disease-19 (COVID-19). J Formos Med Assoc 119(5):1000–1001. https://doi.org/10.1016/j.jfma.2020.03.010
Liang W, Guan W, Chen R, Wang W, Li J, Xu K, Li C, Ai Q, Lu W, Liang H, Li S, He J (2020) Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 21(3):335–337. https://doi.org/10.1016/s1470-2045(20)30096-6
Ljungman P, Mikulska M, de la Camara R, Basak GW, Chabannon C, Corbacioglu S, Duarte R, Dolstra H, Lankester AC, Mohty M, Montoto S, Murray J, Peffault de Latour R, Snowden JA, Yakoub-Agha I, Verhoeven B, Kröger N, Styczynski J (2020) The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy. Bone Marrow Transplant:1–6. https://doi.org/10.1038/s41409-020-0919-0
Mahmoudjafari Z, Alexander M, Roddy J, Shaw R, Shigle TL, Timlin C, Culos K (2020) American Society for Transplantation and Cellular Therapy Pharmacy Special Interest Group Position Statement on Pharmacy Practice Management and Clinical Management for COVID-19 in Hematopoietic Cell Transplantation and Cellular Therapy Patients in the United States. Biol Blood Marrow Transplant 26(6):1043–1049. https://doi.org/10.1016/j.bbmt.2020.04.005
Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, Qayed M, De Moerloose B, Hiramatsu H, Schlis K, Davis KL, Martin PL, Nemecek ER, Yanik GA, Peters C, Baruchel A, Boissel N, Mechinaud F, Balduzzi A, Krueger J, June CH, Levine BL, Wood P, Taran T, Leung M, Mueller KT, Zhang Y, Sen K, Lebwohl D, Pulsipher MA, Grupp SA (2018) Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 378(5):439–448. https://doi.org/10.1056/NEJMoa1709866
Mishra AK, Sahu KK, George AA, Lal A (2020a) A review of cardiac manifestations and predictors of outcome in patients with COVID-19. Heart Lung. https://doi.org/10.1016/j.hrtlng.2020.04.019
Mishra AK, Sahu KK, George AA, Sargent J, Lal A (2020b) Cerebrovascular events in COVID-19 patients. Monaldi Arch Chest Dis 90(2). https://doi.org/10.4081/monaldi.2020.1341
Mishra AK, Sahu KK, Lal A, Sargent J (2020c) Mechanisms of stroke and the role of anticoagulants in COVID-19. J Formos Med Assoc. https://doi.org/10.1016/j.jfma.2020.06.026
Mishra AK, Sahu KK, Lal A, Sargent J (2020d) Patterns of heart injury in COVID-19 and relation to outcome. J Med Virol. https://doi.org/10.1002/jmv.25847
Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY (2017) Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 377(26):2531–2544. https://doi.org/10.1056/NEJMoa1707447
Paul S, Rausch CR, Jain N, Kadia T, Ravandi F, DiNardo CD, Welch MA, Dabaja BS, Daver N, Garcia-Manero G, Wierda W, Pemmaraju N, Montalban Bravo G, Thompson P, Verstovsek S, Konopleva M, Kantarjian H, Jabbour E (2020) Treating leukemia in the time of COVID-19. Acta Haematol:1–13. https://doi.org/10.1159/000508199
Romero D (2018) Haematological cancer: Favourable outcomes with CAR T cells. Nat Rev Clin Oncol 15(2):65. https://doi.org/10.1038/nrclinonc.2017.208
Rzymski P, Nowicki M, Mullin GE, Abraham A, Rodríguez-Román E, Petzold MB, Bendau A, Sahu KK, Ather A, Naviaux AF, Janne P, Gourdin M, Delanghe JR, Ochs HD, Talmadge JE, Garg M, Hamblin MR, Rezaei N (2020) Quantity does not equal quality: scientific principles cannot be sacrificed. Int Immunopharmacol 86:106711. https://doi.org/10.1016/j.intimp.2020.106711
Sahu KK, Cerny J (2020) Managing patients with hematological malignancies during COVID-19 pandemic. Expert Rev Hematol. https://doi.org/10.1080/17474086.2020.1787147
Sahu K, Kumar R (2020a) Current perspective on pandemic of COVID-19 in the United States. J Family Med Primary Care 9(4):1784–1791. https://doi.org/10.4103/jfmpc.jfmpc_424_20
Sahu K, Kumar R (2020b) Preventive and treatment strategies of COVID-19: from community to clinical trials. J Family Med Primary Care 9(5):2149–2157. https://doi.org/10.4103/jfmpc.jfmpc_728_20
Sahu KK, Siddiqui AD (2020) From Hematologist’s desk: the effect of COVID-19 on the blood system. Am J Hematol. https://doi.org/10.1002/ajh.25849
Sahu KK, Prakash G, Khadwal A, Varma SC, Malhotra P (2016) A rare case of hemorrhagic cystitis in allogeneic hematopoietic stem cell transplant patient. Indian J Hematol Blood Transfus 32(Suppl 1):196–200. https://doi.org/10.1007/s12288-015-0530-5
Sahu KK, Jindal V, Siddiqui AD (2020a) Managing COVID-19 in patients with Cancer: a double blow for oncologists. JCO Oncol Pract 16(5):223–225. https://doi.org/10.1200/op.20.00167
Sahu KK, Jindal V, Siddiqui AD, Cerny J, Gerber JM (2020b) Convalescent plasma therapy: a passive therapy for an aggressive COVID-19. J Med Virol. https://doi.org/10.1002/jmv.26047
Sahu KK, Lal A, Mishra AK (2020c) COVID-2019 and pregnancy: a plea for transparent reporting of all cases. Acta Obstet Gynecol Scand 99(7):951. https://doi.org/10.1111/aogs.13850
Sahu KK, Lal A, Mishra AK (2020d) Latest updates on COVID-2019: a changing paradigm shift. J Med Virol 92(6):533–535. https://doi.org/10.1002/jmv.25760
Sahu KK, Lal A, Mishra AK (2020e) An update on CT chest findings in coronavirus disease-19 (COVID-19). Heart Lung. https://doi.org/10.1016/j.hrtlng.2020.03.007
Sahu KK, Lal A, Mishra AK, George SV (2020f) Methemoglobinemia in transplant recipient patients: future of dapsone as pneumocystis carinii pneumonia prophylaxis. Prog Transplant 30(1):71–72. https://doi.org/10.1177/1526924819893316
Sahu KK, Mahagaokar K, Patel B, Winokur D, Suzuki S, Daly JS, Ramanathan M, Cerny J (2020g) Strongyloides stercoralis hyperinfection syndrome in mantle cell lymphoma in post-transplant setting. Ann Hematol. https://doi.org/10.1007/s00277-020-04049-8
Sahu KK, Mishra AK, Lal A (2020h) COIVD 19 disease: tackling a pandemic in 21st century. QJM. https://doi.org/10.1093/qjmed/hcaa117
Sahu KK, Mishra AK, Lal A (2020i) Comprehensive update on current outbreak of novel coronavirus infection (2019-nCoV). Ann Transl Med 8(6):393. https://doi.org/10.21037/atm.2020.02.92
Sahu KK, Mishra AK, Lal A (2020j) COVID-2019: update on epidemiology, disease spread and management. Monaldi Arch Chest Dis 90(1). https://doi.org/10.4081/monaldi.2020.1292
Sahu KK, Mishra AK, Lal A (2020k) Re: from the frontlines of COVID-19-how prepared are we as obstetricians? a commentary. Bjog 127(8):1041. https://doi.org/10.1111/1471-0528.16257
Sahu KK, Mishra AK, Lal A (2020l) Trajectory of the COVID-19 pandemic: chasing a moving target. Ann Transl Med 8(11):694. https://doi.org/10.21037/atm-20-2793
Sahu KK, Mishra AK, Lal A (2020m) A twin challenge to handle: COVID-19 with pregnancy. J Med Virol. https://doi.org/10.1002/jmv.25784
Sahu KK, Mishra AK, Lal A, Sahu SA (2020n) India fights Back: COVID-19 pandemic. Heart Lung. https://doi.org/10.1016/j.hrtlng.2020.04.014
Sahu KK, Mishra AK, Martin K, Chastain I (2020o) COVID-19 and clinical mimics. Correct diagnosis is the key to appropriate therapy. Monaldi Arch Chest Dis 90(2). https://doi.org/10.4081/monaldi.2020.1327
Sahu KK, Mishra AK, Martin K, Chastain I (2020p) COVID-19 and restrictive lung disease: a deadly combo to trip off the fine balance. Monaldi Arch Chest Dis 90(2). https://doi.org/10.4081/monaldi.2020.1346
Sahu KK, Siddiqui AD, Cerny J (2020q) COVID-19 pandemic and impact on hematopoietic stem cell transplantation. Bone Marrow Transplant:1–3. https://doi.org/10.1038/s41409-020-0913-6
Sahu KK, Siddiqui AD, Cerny J (2020r) Managing sickle cell patients with COVID-19 infection: the need to pool our collective experience. Br J Haematol. https://doi.org/10.1111/bjh.16880
Sahu KK, Siddiqui AD, Rezaei N, Cerny J (2020s) Challenges for management of immune thrombocytopenia during COVID-19 pandemic. J Med Virol. https://doi.org/10.1002/jmv.26251
Samaha R, Kattan J (2020) Hematopoietic stem cell transplantation dilemma during the COVID-19 era. Future Oncol. https://doi.org/10.2217/fon-2020-0414
Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jäger U, Jaglowski S, Andreadis C, Westin JR, Fleury I, Bachanova V, Foley SR, Ho PJ, Mielke S, Magenau JM, Holte H, Pantano S, Pacaud LB, Awasthi R, Chu J, Anak Ö, Salles G, Maziarz RT (2019) Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 380(1):45–56. https://doi.org/10.1056/NEJMoa1804980
Sheshadri A, Chemaly RF, Alousi AM, Shah PK, Rondon G, Bashoura L, Kmeid J, Azzi J, Blanco DW, Kaous M, Dickey BF, Champlin RE, Shah DP (2019) Pulmonary impairment after respiratory viral infections is associated with high mortality in allogeneic hematopoietic cell transplant recipients. Biol Blood Marrow Transplant 25(4):800–809. https://doi.org/10.1016/j.bbmt.2018.11.022
Tanhehco YC, Schwartz J (2020) How the COVID-19 pandemic changed cellular therapy at Columbia University Irving Medical Center/NewYork-Presbyterian Hospital. Transfusion. https://doi.org/10.1111/trf.15956
The L (2020) India under COVID-19 lockdown. Lancet 395(10233):1315. https://doi.org/10.1016/s0140-6736(20)30938-7
Weinkove R, McQuilten ZK, Adler J, Agar MR, Blyth E, Cheng AC, Conyers R, Haeusler GM, Hardie C, Jackson C, Lane SW, Middlemiss T, Mollee P, Mulligan SP, Ritchie D, Ruka M, Solomon B, Szer J, Thursky KA, Wood EM, Worth LJ, Yong MK, Slavin MA, Teh BW (2020) Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance. Med J Aust 212(10):481–489. https://doi.org/10.5694/mja2.50607
Yu NH, Chun SY, Ha YS, Kim HT, Kim DH, Kim J, Chung JW, Lee JN, Song PH, Yoo ES, Kim BS, Kwon TG (2018) Optimal stem cell transporting conditions to maintain cell viability and characteristics. Tissue Eng Regen Med 15(5):639–647. https://doi.org/10.1007/s13770-018-0133-y
Acknowledgments
The authors acknowledge image construction provided by Biorender.com.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Sahu, K.K., Ailawadhi, S., Malvik, N., Cerny, J. (2021). Challenges of Cellular Therapy During the COVID-19 Pandemic. In: Rezaei, N. (eds) Coronavirus Disease - COVID-19. Advances in Experimental Medicine and Biology, vol 1318. Springer, Cham. https://doi.org/10.1007/978-3-030-63761-3_36
Download citation
DOI: https://doi.org/10.1007/978-3-030-63761-3_36
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-63760-6
Online ISBN: 978-3-030-63761-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)